Modeling the Accumulation of Degradable Polymer Drug Carriers in the Brain

ChemMedChem
Celine BolwerkRoland Brock

Abstract

The blood-brain barrier (BBB) limits the access of drugs to the brain. Intensive research is being conducted on the development of nanoparticulate drug carriers that mediate transfer across the BBB. A question that has been neglected so far is the potential accumulation of the carrier in the brain upon long-term exposure. Here, we address this question by implementing a kinetic model to relate drug loading, required concentration of drug in the brain, and drug clearance to the degradation half-life of the carrier. As a test case with clinical relevance we chose poly-lactic-co-glycolic-acid (PLGA) as a carrier material and a chemotherapeutic for which the required parameters could be recovered from the literature. For methotrexate with a drug load of 8.5 %, a required concentration of free drug of 1 μm, a release from PLGA of 6 hours, a drug clearance from the brain of 3 hours and a half-life of polymer degradation of 28 days, a steady-state accumulation of 1.3 g polymer would be reached in the brain (1.5 L) after seven months. While this number is surprisingly small, further physiological research is warranted to assess to which degree this will be in a tolerable range.

References

Dec 24, 2005·Nature Reviews. Neuroscience·N Joan AbbottElisabeth Hansson
Jul 11, 2007·Pharmaceutical Research·Angela R Jones, Eric V Shusta
Oct 27, 2009·International Journal of Clinical Oncology·Hiromitsu YamakawaRyo Konno
Mar 27, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·G TosiM A Vandelli
Nov 19, 2011·Drug Discovery Today·Luca Costantino, Diana Boraschi
Mar 21, 2013·Molecular Pharmaceutics·Abdul Khader Mohammad, Joshua J Reineke
Oct 16, 2013·Journal of Microencapsulation·Majid AfshariLeila Hosseinzadeh
Nov 26, 2013·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·J G SchierW D Flanders
Apr 22, 2016·Journal of Biomedical Materials Research. Part B, Applied Biomaterials·Yihan XuDonghun Koo
Jul 10, 2016·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Annika LindqvistMargareta Hammarlund-Udenaes
Sep 3, 2017·International Journal of Biological Macromolecules·Hanmei LiYuxuan Zhu

❮ Previous
Next ❯

Citations

Aug 22, 2018·Frontiers in Aging Neuroscience·Elena D OsipovaAlla B Salmina
Sep 16, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Alexander H van AsbeckRoland Brock

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Related Papers

Nihon yakurigaku zasshi. Folia pharmacologica Japonica
Shinsuke Nakagawa, Masami Niwa
Hepatology : Official Journal of the American Association for the Study of Liver Diseases
K D MullenA J McCullough
International Journal of Clinical Pharmacology and Therapeutics
A B De BoerD D Breimer
Histology and Histopathology
J Cervós-NavarroY Nakagawa
© 2022 Meta ULC. All rights reserved